Array comparative genomic hybridization analysis of chromosomal imbalances and their target genes in gastrointestinal stromal tumors

Gastrointestinal stromal tumor (GIST) is the most common mesenchymal tumor of the gastrointestinal tract. The tumors characteristically harbor KIT or PDGFRA mutations, and mutant tumors respond to imatinib mesylate (Glivec™). Chromosomal imbalances resulting in altered gene dosage are known to have a role in the molecular pathogenesis of these tumors, but the target genes remain to be identified. The present study aimed to identify some of these genes. In total, 35 GIST samples were screened for chromosomal imbalances by array‐based comparative genomic hybridization. A cDNA array was used to define the minimal common overlapping areas of DNA copy number change. Eight confirmative, replicate hybridizations were performed using an oligonucleotide array. The most recurrent copy number losses were localized to 14q, 22q, and 1p. Gains were less common with 8q being the most recurrent. Two recurrent deleted regions of 14q were 14q11.2 harboring the PARP2, APEX1, and NDRG2 genes and 14q32.33 harboring SIVA. Additional target candidates were NF2 at chromosome 22, CDKN2A/2B at 9p, and ENO1 at 1p for copy number losses, and MYC at 8q for copy number gains. Array CGH proved to be an effective tool for the identification of chromosome regions involved in the development and progression of GISTs. © 2007 Wiley‐Liss, Inc.

[1]  J. Vermeesch,et al.  Array CGH analysis in primary gastrointestinal stromal tumors: Cytogenetic profile correlates with anatomic site and tumor aggressiveness, irrespective of mutational status , 2007, Genes, chromosomes & cancer.

[2]  J. Lasota,et al.  Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis. , 2009, Archives of pathology & laboratory medicine.

[3]  Stine H. Kresse,et al.  Array comparative genomic hybridization reveals distinct DNA copy number differences between gastrointestinal stromal tumors and leiomyosarcomas. , 2006, Cancer research.

[4]  J. Stachura,et al.  GISTs with PDGFRA exon 14 mutations represent subset of clinically favorable gastric tumors with epithelioid morphology , 2006, Laboratory Investigation.

[5]  Florian Haller,et al.  Prognostic Role of E2F1 and Members of the CDKN2A Network in Gastrointestinal Stromal Tumors , 2005, Clinical Cancer Research.

[6]  Arie Perry,et al.  Integrative genomic analysis identifies NDRG2 as a candidate tumor suppressor gene frequently inactivated in clinically aggressive meningioma. , 2005, Cancer research.

[7]  M. Pierotti,et al.  9p21 locus analysis in high‐risk gastrointestinal stromal tumors characterized for c‐kit and platelet‐derived growth factor receptor α gene alterations , 2005, Cancer.

[8]  J. Ko,et al.  Functional evidence of decreased tumorigenicity associated with monochromosome transfer of chromosome 14 in esophageal cancer and the mapping of tumor‐suppressive regions to 14q32 , 2005, Genes, chromosomes & cancer.

[9]  M. Debiec‐Rychter,et al.  KIT overexpression and amplification in gastrointestinal stromal tumors (GISTs). , 2005, Biochimica et biophysica acta.

[10]  P. Marynen,et al.  Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants. , 2005, Gastroenterology.

[11]  S. Knuutila,et al.  Gene amplifications in osteosarcoma—CGH microarray analysis , 2005, Genes, chromosomes & cancer.

[12]  A. Hartmann,et al.  Loss of p16 protein defines high-risk patients with gastrointestinal stromal tumors: a tissue microarray study. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[13]  E. Musulen,et al.  Gastrointestinal stromal tumors , 2006, Abdominal Imaging.

[14]  Chung-Liang Ho,et al.  Allelic loss of 14q32 in the pathogenesis of gastrointestinal and ampullary malignancies: mapping of the target region to a 17 cM interval , 2005, Journal of Cancer Research and Clinical Oncology.

[15]  Elena Marchiori,et al.  Breakpoint identification and smoothing of array comparative genomic hybridization data , 2004, Bioinform..

[16]  Yanchun Deng,et al.  NDRG2 expression and mutation in human liver and pancreatic cancers. , 2004, World journal of gastroenterology.

[17]  E. Kay,et al.  Loss of heterozygosity of chromosome 9p and loss of p16INK4A expression are associated with malignant gastrointestinal stromal tumors , 2004, Modern Pathology.

[18]  Patrick G Buckley,et al.  Genomic microarrays in the spotlight. , 2004, Trends in genetics : TIG.

[19]  L. Larocca,et al.  Role of p16/INK4a in gastrointestinal stromal tumor progression. , 2004, American journal of clinical pathology.

[20]  C. Tzeng,et al.  Biological significance of chromosomal imbalance aberrations in gastrointestinal stromal tumors. , 2004, Journal of biomedical science.

[21]  S. Leung,et al.  N‐Myc downstream‐regulated gene 2 (NDRG2) inhibits glioblastoma cell proliferation , 2003, International journal of cancer.

[22]  Samuel Singer,et al.  PDGFRA Activating Mutations in Gastrointestinal Stromal Tumors , 2003, Science.

[23]  G. Enders The INK4a/ARF locus and human cancer. , 2003, Methods in molecular biology.

[24]  B. Gunawan,et al.  Biological and clinical significance of cytogenetic abnormalities in low-risk and high-risk gastrointestinal stromal tumors. , 2002, Human pathology.

[25]  Michael Baudis,et al.  Progenetix.net: an online repository for molecular cytogenetic aberration data , 2001, Bioinform..

[26]  P. D. Dal Cin,et al.  Molecular cytogenetic definition of three distinct chromosome arm 14q deletion intervals in gastrointestinal stromal tumors , 2001, Genes, chromosomes & cancer.

[27]  M. Debiec‐Rychter,et al.  Chromosomal aberrations in malignant gastrointestinal stromal tumors: correlation with c-KIT gene mutation. , 2001, Cancer genetics and cytogenetics.

[28]  L. Sobin,et al.  Mutations in exons 9 and 13 of KIT gene are rare events in gastrointestinal stromal tumors. A study of 200 cases. , 2000, The American journal of pathology.

[29]  L. Kindblom,et al.  Loss of 14q and 22q in gastrointestinal stromal tumors (pacemaker cell tumors). , 2000, Cancer genetics and cytogenetics.

[30]  S. Knuutila,et al.  DNA sequence copy number changes in gastrointestinal stromal tumors: tumor progression and prognostic significance. , 2000, Cancer research.

[31]  R. Passantino,et al.  ENO1 gene product binds to the c‐myc promoter and acts as a transcriptional repressor: relationship with Myc promoter‐binding protein 1 (MBP‐1) , 2000, FEBS letters.

[32]  E. de Álava,et al.  Predicting Metastatic Risk of Gastrointestinal Stromal Tumors: Role of Cell Proliferation and Cell Cycle Regulatory Proteins , 2000, International journal of surgical pathology.

[33]  S. Knuutila,et al.  High‐resolution deletion mapping of chromosome 14 in stromal tumors of the gastrointestinal tract suggests two distinct tumor suppressor loci , 2000, Genes, chromosomes & cancer.

[34]  J. Fletcher,et al.  KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors. , 2000, The American journal of pathology.

[35]  H. Kondoh,et al.  Identification of new genes ndr2 and ndr3 which are related to Ndr1/RTP/Drg1 but show distinct tissue specificity and response to N-myc. , 1999, Biochemical and biophysical research communications.

[36]  L. Sobin,et al.  Loss of heterozygosity at 1p36 predicts poor prognosis in gastrointestinal stromal/smooth muscle tumors. , 1999, Laboratory investigation; a journal of technical methods and pathology.

[37]  Ash A. Alizadeh,et al.  Genome-wide analysis of DNA copy-number changes using cDNA microarrays , 1999, Nature Genetics.

[38]  M. Johansson A human poly(ADP-ribose) polymerase gene family (ADPRTL): cDNA cloning of two novel poly(ADP-ribose) polymerase homologues. , 1999, Genomics.

[39]  R. Hruban,et al.  High‐resolution deletion mapping of chromosome arm 1p in pancreatic cancer identifies a major consensus region at 1p35 , 1999, Genes, chromosomes & cancer.

[40]  S. Knuutila,et al.  Different patterns of DNA copy number changes in gastrointestinal stromal tumors, leiomyomas, and schwannomas. , 1998, Human pathology.

[41]  S. Knuutila,et al.  Comparative genomic hybridization study on pooled DNAs from tumors of one clinical-pathological entity. , 1998, Cancer genetics and cytogenetics.

[42]  Z. Ao,et al.  CD27, a member of the tumor necrosis factor receptor family, induces apoptosis and binds to Siva, a proapoptotic protein. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[43]  S. Knuutila,et al.  DNA copy number losses in chromosome 14: an early change in gastrointestinal stromal tumors. , 1996, Cancer research.

[44]  Gregory J. Hannon,et al.  pl5INK4B is a potentia| effector of TGF-β-induced cell cycle arrest , 1994, Nature.

[45]  M. Skolnick,et al.  A cell cycle regulator potentially involved in genesis of many tumor types. , 1994, Science.

[46]  G. Hannon,et al.  p15INK4B is a potential effector of TGF-beta-induced cell cycle arrest. , 1994, Nature.

[47]  G. Hannon,et al.  A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4 , 1993, Nature.

[48]  C. Robson,et al.  Isolation of cDNA clones encoding a human apurinic/apyrimidinic endonuclease that corrects DNA repair and mutagenesis defects in E. coli xth (exonuclease III) mutants. , 1991, Nucleic acids research.